Navigation Links
Syngenta Licenses Chromatin Gene Stacking Technology
Date:10/19/2007

RALEIGH, N.C., Oct. 19 /PRNewswire-FirstCall/ -- Syngenta Biotechnology Inc. announced today that it has entered into a research and commercial license agreement for Chromatin's proprietary gene stacking technology.

Chromatin has developed a novel approach to gene stacking, using the plant's own DNA to deliver several genes on a mini-chromosome. Under the agreement, Syngenta has obtained non-exclusive rights to use Chromatin's gene stacking technology for trait genes in corn and soybeans

"Growers need increasingly more sophisticated tools to meet the demands on the agriculture market, and stacked traits along with improved seed germplasm will be instrumental," said Roger Kemble, Head of Syngenta Crop Genetics Research. "We will evaluate this technology in combination with our own innovative research programs and strong pipeline as part of our intense commitment to speed delivery of products to market."

"Syngenta is a leading agribusiness company committed to developing crops that meet multiple needs. Chromatin is pleased to partner with Syngenta, whose trait gene inventory and crop production programs make them an ideal partner for us," said Daphne Preuss, Chromatin's Chief Scientific Officer and President.

Further terms of the deal were not disclosed.

Syngenta is a world-leading agribusiness committed to sustainable agriculture through innovative research and technology. The company is a leader in crop protection, and ranks third in the high-value commercial seeds market. Sales in 2006 were approximately $8.1 billion. Syngenta employs around 21,000 people in over 90 countries. Syngenta is listed on the Swiss stock exchange (SYNN) and in New York (NYSE: SYT). Further information is available at http://www.syngenta.com .

Media Enquiries: Medard Schoenmaeckers (Switzerland) +41 61 323 2323

Sarah Hull (US) +1 202 628 2372

Analysts/Investors: Jonathan Seabrook +41 61 323 7502

+1 202 737 6520

Jennifer Gough +41 61 323 5059

+1 202 737 6521

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefore.


'/>"/>
SOURCE Syngenta Biotechnology Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
7. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
8. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
9. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):